Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) announced that the China Securities Regulatory Commission (CSRC) issued a filing notice on 2 April 2026 approving the company’s H Share Full Circulation application. The filing covers the conversion of 136.30 million unlisted domestic shares, held by 12 existing shareholders, into H shares.

According to the CSRC notice, the conversion must be completed within 12 months from the filing date; otherwise, updated filing materials will be required. Following the conversion, JIUYUAN GENE will apply to The Stock Exchange of Hong Kong Limited for the listing of, and permission to deal in, the new H shares on its Main Board.

The detailed implementation plan for the H Share Full Circulation is still being finalized. The company will release further updates in accordance with Hong Kong Listing Rules and relevant inside information provisions.

Shareholders and potential investors have been advised to exercise caution when dealing in the company’s shares, as the H Share Full Circulation remains subject to additional regulatory procedures in both domestic and overseas jurisdictions.